HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
CTMX
CytomX Therapeutics Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $745.5M
Market Cap
$745.5M
Enterprise Val
$611.2M
P/E Ratio
-36.60
P/B Ratio
7.53
Trailing PEG (1Y)
0.19
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$99.0M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-23.19%
Return on Assets-13.97%
Current Ratio3.09
Debt/Equity0.04
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Dec 31, 2025
Revenue$663.0K
Cost of Revenue$0.00
Gross Profit$663.0K
R&D$21.2M
SG&A$7.4M
Operating Expenses$28.6M
Operating Income-$27.9M
Interest Expense$0.00
Tax Expense$54.0K
Net Income-$29.5M
EPS (Basic)$-0.22
EPS (Diluted)$-0.22
EBIT-$29.5M
EBITDA-$27.8M
Consolidated Income-$26.5M
Non-Controlling Interests$3.0M

Balance Sheet

Dec 31, 2025
Cash & Equivalents$14.2M
Accounts Receivable$2.0M
Inventory$0.00
Current Assets$143.9M
LT Investments$0.00
Property, Plant & Equipment$4.7M
Intangibles$1.4M
Non-Current Assets$7.6M
Total Assets$151.6M
Accounts Payable$1.3M
Current Debt$4.2M
Current Liabilities$46.6M
LT Debt$0.00
Non-Current Liabilities$5.9M
Total Liabilities$52.6M
Total Debt$4.2M
Retained Earnings-$711.9M
Shareholder Equity$99.0M
Shares Outstanding169,435,395

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$23.2M
Investing Cash Flow-$14.4M
Financing Cash Flow$16.6M
CapEx-$201.0K
Free Cash Flow-$23.4M
Depreciation & Amort.$1.7M
Stock-Based Comp$1.5M
Acquisitions / Disposals$0.00
Investment Activity-$14.2M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$16.6M
Dividends Paid$0.00
Net Change in Cash-$21.0M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h